CStone Pharmaceuticals (2616) H1 2025 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2025, dropped 80.5% year-over-year to RMB49.4 million, mainly due to lower sales of pralsetinib, price adjustments, and absence of major licensing or milestone deals.

• Net loss for the period was RMB270.2 million (Non-IFRS), reversing a prior-year profit, driven by a shift from gross profit to gross loss.

• Advanced global expansion with new regulatory approvals and strategic partnerships, notably for sugemalimab in Europe, UK, LATAM, and China.

• Four commercialized products with nine approved indications and five territories covered, including major launches in EU and UK.

• Sugemalimab became the first PD-L1 developed by a Chinese biopharma to be marketed internationally, with approvals in EU, UK, and China.

Financial highlights

• Revenue for 2025 H1 was RMB49.4 million, down from RMB254.2 million year-over-year.

• Net loss for 2025 H1 was RMB265.1 million (Non-IFRS), compared to a profit of RMB10.8 million in 2024 H1.

• Cash and cash equivalents and time deposits stood at RMB652.8 million as of June 30, 2025, with an additional RMB425.8 million raised in July 2025.

• Operating expenses remained stable at RMB179.3 million, with R&D expenses rising 44% year-over-year to RMB105.2 million.

• Cost of revenue increased to RMB142.2 million, mainly due to inventory write-downs and early billing for pralsetinib supply.

Outlook and guidance

• Anticipates revenue growth in H2 2025 from new licensing agreements, especially Gentili, and potential NRDL inclusion for pralsetinib.

• Multiple global regulatory submissions and commercial launches planned for sugemalimab and other pipeline assets.

• Focus on advancing CS5001 and CS2009 towards pivotal trials and expanding early-stage candidates.

• Ongoing expansion of commercial partnerships in SEA, Australia, Canada, Japan, India, Europe, and LATAM.

• Caution that pipeline products may not ultimately be developed or marketed successfully.